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Objectives: To identify the asthma patients, on short-acting b2-agonists alone, who would
benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC)
propionate 50/100 g bd compared with fluticasone propionate (FP) 100 g bd alone. The
results of an integrated analysis of data from four previous trials are presented.
Methods: The four original trials were randomised, double-blind, parallel group studies
and included patients who had received IMTwith SFC 50/100 g bd or FP 100 g bd. Patients
wereX12 years with a 6 month history of asthma andX15% reversibility in FEV1. Patients
had either not received inhaled corticosteroids in the preceding month or were steroid
naı¨ve. Patients were assessed to determine whether any GINA-defined asthma character-
istics or combination of asthma characteristics could predict those individuals who would
achieve well controlled asthma status with IMT with SFC rather than with inhaled steroid
alone. Patients with persistent asthma were assessed based on GINA-defined baseline
asthma characteristics and well controlled asthma status in response to each treatment
was investigated according to combinations of these baseline features. Subsequently, a
further range of endpoints, including asthma symptoms, rescue medication use and asthma
control, were analysed over weeks 1–12 for the combinations of features where the
treatment difference in well controlled asthma status was greatest.
Results: The results of the initial analyses demonstrated that patients exhibiting two or
three features of uncontrolled asthma at baseline were more likely to achieve wellElsevier Ltd. All rights reserved.
ndthelondon.nhs.uk (N.C. Barnes).
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difference being observed in patients with three baseline features (odds ratio 2.60, 95% CI:
1.87, 3.62, po0.001). Patients with one baseline feature showed no difference between
the FP and SFC groups. Further analyses on data from patients with two or three baseline
asthma features, showed that treatment with SFC resulted in significantly greater
improvements in mean morning PEF, percentage symptom-free days, nights with no
awakenings and rescue-free days compared with FP. In addition, asthma control was
achieved earlier in patients in the SFC group. SFC and FP were well tolerated as shown
previously in the four individual trials.
Conclusions: Patients on short-acting b2-agonists alone with two or three features of
uncontrolled asthma (moderate to severe airflow limitation/daily symptoms/daily rescue
medication use) are most likely to achieve better control, earlier, with SFC 50/100 g bd
initial maintenance treatment compared with FP 100 g bd alone.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is associated with significant morbidity and is
increasing in prevalence in many regions. Currently approxi-
mately 300 million people worldwide have asthma with a
prevalence of more than 10% found in developed coun-
tries,1,2 and the rate expected to increase in developing
countries as they become more urbanised.3 International
guidelines state that the aim of asthma treatment is to
achieve and maintain clinical control,4 although in all
regions these goals are frequently not met.5–8 A step-wise
approach to treatment is recommended with inhaled
corticosteroids (ICS) being the favoured anti-inflammatory
agent for all levels of asthma severity. It is now acknowl-
edged that, in patients already on ICS therapy, adding a
long-acting b2-agonist (LABA) results in better asthma
control than increasing the dose of ICS9,10 or adding
a leukotriene receptor antagonist.11 Although inhaled
steroids are an effective treatment, they do not control
asthma in all patients. Therefore, it has been suggested
that initial treatment with combination therapy may be
advantageous.
Recently, four studies have shown that patients, with
persistent asthma uncontrolled on short-acting b2-agonists
alone, benefit from initial maintenance therapy (IMT) with a
combination of salmeterol and fluticasone propionate 50/
100 g bd (SFC) compared with FP alone.12–15 This paper
presents the results of a post-hoc integrated analysis of data
from these four trials. The rationale for this analysis was to
identify those patients who would benefit from first line
maintenance treatment with SFC therapy compared with FP
alone.Methods
Study designs and participants
The study design and key inclusion criteria of each of the
four trials are summarised in Table 1. Patients in all trials
wereX12 years with a 6 month history of asthma andX15%
reversibility in FEV1 within 30min of taking inhaled
salbutamol. Murray et al.12 and Nelson et al.13 included
patients who had received short-acting b2-agonists only inthe previous month. Pearlman et al.14 stratified patients
based on their baseline asthma therapy: data from patients
who had been using b2-agonists alone, for at least 1 week
were included in the integrated analysis.
The GOAL study15 was a 1-year, stratified study comparing
the efficacy and safety of individual, predefined step-
wise increases of SFC with FP alone in achieving two
predefined measures of asthma control. Data used in
the integrated analysis were from the first 12 weeks of
treatment with SFC 50/100 g bd or FP 100 g bd in Stratum 1
(steroid naı¨ve).
Treatment response by baseline asthma
characteristics
Patients with persistent asthma were assessed based on the
presence of one or more of three baseline characteristics,
derived from the goals of treatment defined in the Global
Initiative for Asthma (GINA) guidelines: moderate to severe
airflow limitation (FEV1 or PEFp80% predicted normal),
daily symptoms (defined as symptom score X1 every day
during the run-in period) and daily use of rescue medication
(defined as rescue medication used at least once during
every day of the run-in period)) (Figure 1). These criteria
were chosen because it has previously been demonstrated
that, together, these identify the majority of patients with
poor asthma control.16
Statistical subgroup analyses were performed for each
characteristic and each combination of characteristics in
order to investigate treatment differences in the proportion
of subjects achieving well controlled asthma, according to
baseline features of GINA-defined persistent asthma, with
either SFC or FP alone as IMT. Well controlled asthma is a
composite measure based on a number of individual
endpoints as previously defined in the GOAL study (Table
2). The proportion of patients achieving well controlled
asthma was calculated retrospectively for the three other
studies.
Efficacy measures
For those patients with the combination of baseline GINA
characteristics that demonstrated the best treatment
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Table 1 Study designs and participants.
Trial
12 13 14 15 (GOAL study)
Design Rand., DB, PG, 12-week Rand., DB, PG, 12-week Rand., DB, PG, placebo-
controlled, stratified, 12-
week
Rand, DB, PG, stratified,
1 year , dose step-up
Setting 33 centres across USA 33 centres across USA 36 centres across USA 326 centres in 44
countries
Participants
(key
inclusion
criteria)
X12 years; short-acting
b2-agonist only in
previous month; FEV1
40–85% predicted;X15%
reversibility in FEV1
after inhaled salbutamol
X12 years; short-acting
b2-agonist only in
previous month; FEV1
40–85% predicted;X15%
reversibility in FEV1
after inhaled salbutamol
X12 years; FEV1 40–85%
predicted; X15%
reversibility in FEV1 after
inhaled salbutamol.
Stratum 2: b2-agonist only
(salmeterol or short-
acting) in last week
X12–o80years, X15%
reversibility in FEV1 after
inhaled salbutamol,
Stratum 1: steroid naı¨ve
Treatments SFC 50/100 g bd or FP
100 g bd or salmeterol
50 g bd (via Diskus)
SFC 50/100 g bd or FP
100 g bd or salmeterol
50 g bd (via HFA MDI)
SFC 50/100 g bd or FP
100 g bd or salmeterol
50 g bd or placebo(via
HFA MDI)
Stratum 1, first 12-
weeks: SFC 50/100 g bd
or FP 100 g bd (via
Diskus)
Efficacy endpoints:
Primary Pre-dose FEV1 and AUC
FEV1
Pre-dose FEV1 and AUC
FEV1
Pre-dose FEV1 and AUC
FEV1
Proportion of patients
achieving WC asthma
Secondary PEF, asthma symptoms,
rescue medication use,
withdrawals due to
worsening asthma
PEF, asthma symptoms,
rescue medication use,
withdrawals due to
worsening asthma
PEF, asthma symptoms,
rescue medication use,
withdrawals due to
worsening asthma
Proportion achieving TC
asthma and time to first
week of WC/TC asthma,
AQLQ, exacerbations,
pre-dose FEV1
Rand ¼ randomised; DB ¼ double-blind; PG ¼ parallel group; SFC ¼ salmeterol/fluticasone propionate combination; FP ¼ fluticasone
propionate; HFA ¼ hydrofluorokane; MDI ¼ metered dose inhaler; FEV1 ¼ forced expiratory volume in one second; AUC FEV1 ¼ area
under serial FEV1 curve; WC ¼ well controlled; TC ¼ totally controlled.
N.C. Barnes et al.2360response in well controlled asthma status, a further range of
endpoints were analysed using the integrated data set over
weeks 1–12.
These included the proportion of patients who achieved
totally controlled asthma (definition shown in Table 2) and
time to achieving first week of well controlled and totally
controlled asthma. Additional efficacy endpoints were the
change from baseline in mean morning pre-dose PEF over
weeks 1–12 and at endpoint (mean over the last available 7
days of on-treatment data), and change from baseline in
level of asthma symptoms, nocturnal awakenings and rescue
medication use.Safety measures
The incidence of adverse events, and relationship to study
medication, was assessed in all trials, and 12 week data is
summarised here. Routine laboratory assessments and
12-lead electrocardiograms (ECGs) were measured in the
three 12-week studies and 24-h urinary cortisols were
assessed at selected centres in the GOAL study. Integrated
safety data have not been produced, but safety data fromthe four original studies are summarised, in order to present
the broadest available data set.Statistical analyses
The comparison of asthma control status (achieved well
controlled/totally controlled asthma versus not achieved
well controlled/totally controlled) was made using logistic
regression analysis, adjusting for baseline pre-bronchodila-
tor FEV1, age, gender and study.
For change from baseline over weeks 1–12 and at
endpoint in mean morning PEF, individual patient means
were compared between treatment groups using Analysis
of Covariance (ANCOVA) adjusting for baseline PEF, age,
gender and study. Percentage of days and nights with
no asthma symptoms, and of rescue-free days were
calculated for each patient during weeks 1–12 and assigned
to one of five categories: 0–25%, 425–50%, 450–75%,
475–o100% and 100%. The proportion of patients in each
category were compared across treatment groups using
proportional odds logistic regression, adjusting for covari-
ates of baseline, age, gender, treatment group and study.
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percentage of rescue-free days, a Cochran–Mantel–Haenszel
test, stratified by study, was used to compare treatment
groups for this endpoint.Table 2 Definitions of well controlled and totally controlled
(Bateman, 2004).
Goals of GINA/NIH Totally
week a
Daytime symptoms Minimal (ideally no) None
Rescue b2-agonist use Minimal (ideally no) None
Morning PEF Near normal X80%
day
Night-time awakening Minimal (ideally no) None
Exacerbationsb Minimal (infrequent) None
Emergency visits No None
Treatment-related
adverse events
Minimal None e
asthma
GINA ¼ Global initiative for asthma; NIH ¼ National Institute of Heal
aSymptom score of 1 defined as ‘symptoms for one short period du
bExacerbations were defined as deterioration in asthma requiring tr
or hospitalisation.
Figure 1 Persistent asthmatics as defined by baseline features
(rescue use, symptoms, airflow limitation) for 1525 patients
treated with FP 100 g bd or SFC 50/100 g bd. Key: A: daily
rescue use only; B: daily symptoms only; C: moderate/severe
airflow limitation only; D: daily symptoms and daily rescue use;
E: daily symptoms and moderate/severe airflow limitation; F:
daily rescue use and moderate/severe airflow limitation; G:
daily symptoms and daily rescue use and moderate/severe
airflow limitation.Results
Treatment response by baseline asthma
characteristics
Analyses of treatment response by the number of baseline
features demonstrated that patients exhibiting two or three
GINA-defined features of uncontrolled asthma at baseline were
significantly more likely to achieve well controlled asthma
when treated with SFC than with FP alone, the greatest
difference being shown in patients with three baseline
features: in the SFC group, 43% of patients were well controlled
during weeks 5–12 compared with 23% in the FP group and the
odds of achieving well controlled asthma on SFC treatment was
more than double that on FP treatment (Table 4). There was no
evidence of a difference between the FP and SFC groups in
patients with one baseline feature. Further analyses were
therefore performed on data from patients with two or three
baseline features of uncontrolled asthma.Integrated analyses over weeks 1–12
The demography and baseline characteristics of patients in
the integrated data sets, for those with either two or three
baseline features of uncontrolled asthma, were similar in
both treatment groups (Table 3).
A summary of the results from the integrated analyses is
shown in Table 5. Results of analyses from patients with three
baseline asthma features are discussed in the text below.
Improvements from baseline in morning pre-dose PEF over
weeks 1–12 were shown in both treatment groups but
the increase was significantly higher in the SFC group.
A significantly greater improvement was also shown for
morning PEF at endpoint with SFC over FP alone (difference
(SE): 26.5 (4.1); 95% CI 18.5, 34.6; po0.001).asthma based on GINA/NIH guideline aims of treatment
controlled each
ll of:
Well controlled each week X2 of:
p2 days with symptom scorea 41
Use on p2 days and p4 occasions/
week
predicted every X80% predicted every day
All of:
None
None
None
nforcing change in
therapy
None enforcing change in asthma
therapy
th; PEF ¼ peak expiratory flow.
ring the day’; overall scale: 0 (none)–5 (severe).
eatment with an oral corticosteroid, emergency department visit
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Table 3 Demography and baseline characteristics for integrated subsets.
Subset with two baseline asthma features Subset with three baseline asthma features
FP 100 g bd
n ¼ 178
SFC 50/100 g bd
n ¼ 209
FP 100 g bd
n ¼ 360
SFC 50/100 g bd
n ¼ 352
Age:
Mean, years (SD) 36.3 (15.40) 34.5 (15.10) 37.3 (14.65) 36.9 (14.37)
Range, n (%)
1217 years 21 (12) 28 (13) 35 (10) 31 (9)
1864 years 151 (85) 173 (83) 315 (88) 304 (86)
X65 years 6 (3) 8 (4) 10 (3) 17 (5)
Gender, n (%):
Female 108 (61) 129 (62) 180 (50) 188 (53)
Male 70 (39) 80 (38) 180 (50) 164 (47)
Pre-dose FEV1 (L), n 177 208 357 348
Mean (SD) 2.59 (0.77) 2.54 (0.80) 2.23 (0.73) 2.19 (0.72)
% Predicted FEV1, n 177 208 357 348
Mean (SD) 80.32 (17.67) 78.20 (17.77) 66.67 (15.01) 65.89 (13.67)
% Reversibility FEV1, n 147 170 313 298
Mean (SD) 26.35 (14.35) 26.89 (13.53) 30.88 (15.55) 30.93 (15.72)
FP ¼ fluticasone propionate; SFC ¼ salmeterol/fluticasone propionate.
Table 4 Estimation of proportion of patients achieving well controlleda asthma for patients with one, two or three baseline
feature(s) of persistent asthma.
Definition of persistent asthma (N) FP 100% (n/Nb) SFC 50/100% (n/Nb)
Patients with only one baseline feature (rescue use only; symptoms
only; or moderate/severe airflow limitation only) (313)
48% (78/161) 51% (75/148)
Odds of SFC to F 1.01
95% CI 0.64, 1.60
p-value 0.966
Patients with a combination of any two baseline features (rescue use
and symptoms; rescue use and moderate/severe airflow limitation;
or symptoms and moderate/severe airflow limitation) (387)
35% (62/177) 46% (96/207)
Odds of SFC to FP 1.65
95% CI 1.09, 2.50
p-value 0.019
Patients with all three Baseline features (rescue use and symptoms
and moderate/severe airflow limitation) (712)
23% (81/357) 43% (150/348)
Odds of SFC to FP 2.60
95% CI 1.87, 3.62
p-value o0.001
aDefined in.15 FP ¼ fluticasone propionate, SFC ¼ salmeterol/fluticasone propionate.
bExcludes patients with missing covariates.
N.C. Barnes et al.2362During the 12 week treatment period, the median
percentage of days with both no asthma symptoms and no
rescue medication usage, and the percentage of nights with
no awakenings, improved in both treatment groups. The
proportion of patients in each symptom-free or rescue-free
category showed significantly greater improvements in the
SFC compared with the FP group (po0.001) (Table 5).
The proportion of patients assessed as having totally
controlled asthma during weeks 5–12 of treatment washigher in the SFC compared with the FP group, the difference
between groups approaching statistical significance for
patients with three asthma baseline features (p ¼ 0.054).
Analysis of the time to the first well controlled week of
asthma during weeks 1–12 showed that control was achieved
significantly earlier in the SFC group compared with the FP
group (po0.001). The median time by which 50% of patients
achieved their first week of well controlled asthma was day
16 in the SFC group compared with day 72 in the FP group.
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Table 5 Summary of integrated efficacy for the sub-group populations.
Endpoint Two GINA baseline features Three GINA baseline features
FP n ¼ 178 SFC n ¼ 209 FP n ¼ 360 SFC n ¼ 352
Morning PEF (weeks 1–12), n 174 203 352 347
Adjusted mean (SE) 386.5 (3.89) 406.9 (3.75) 376.3 (2.91) 402.3 (2.85)
Adjusted mean change (SE) 22.7 (3.89) 43.2 (3.75) 40.4 (2.91) 66.4 (2.85)
Treatment difference (SE) 20.4 (4.13) 26.0
95% CI 12.3, 28.6 19.3, 32.6
p-valuea o0.001 o0.001
% symptom-free days, n (%)
o25% 102 (58) 97 (48) 218 (62) 162 (47)
X25–p50% 16 (9) 19 (9) 35 (10) 28 (8)
X50–p75% 20 (11) 24 (12) 45 (13) 51 (15)
X75–o100% 32 (18) 55 (27) 48 (14) 93 (27)
100% 5 (3) 7 (3) 7 (2) 13 (4)
Odds ratio (95% CI) 1.635 (1.10, 2.43) 2.050 (1.54, 2.74)
p-valueb 0.015 o0.001
% nights with no awakenings, n (%)
o25% 8 (5) 6 (3) 34 (10) 21 (6)
X25–p50% 14 (8) 6 (3) 14 (4) 16 (5)
X50–p75% 15 (9) 16 (8) 39 (11) 28 (8)
X75–o100% 62 (35) 77 (38) 155 (45) 128 (37)
100% 76 (43) 98 (48) 106 (30) 151 (44)
Odds ratio (95% CI) 1.343 (0.90, 2.00) 2.094 (1.56, 2.82)
p-valuec 0.145 o0.001
% rescue-free days, n (%)
o25% 41 (23) 28 (14) 190 (54) 110 (32)
X25–p50% 21 (12) 17 (8) 41 (12) 31 (9)
X50–p75% 33 (19) 33 (16) 53 (15) 55 (16)
X75–o100% 65 (37) 96 (48) 62 (18) 126 (36)
100% 15 (9) 27 (13) 6 (2) 25 (7)
p-valuec 0.002 o0.001
Proportion of patients with TC asthma
(%), weeks 5–12 17/178 (10) 30/209 (14) 18/357 (5) 31/348 (9)
SFC-FP (SE) 5 (3.29) 4 (1.92)
95% CI 2,12 0, 8
p-valued 0.163 0.054
Time to 1st week of WC asthma
Ne 119 165 187 258
Medianf (days) 30 9 72 16
SFC/FP, p-value 0.004 o0.001
FP ¼ fluticasone propionate; SFC ¼ salmeterol/fluticasone propionate; PEF ¼ peak expiratory flow; SE ¼ standard error?
aAnalysis of covariance.
bLogistic regression analysis (proportional odds).
cCochran–Mantel–Haenszel test.
dLogistic regression analysis.
eNumber of patients achieving X1 controlled week.
fMedian time to first controlled week from survival analysis.
IMT with salmeterol/fluticasone propionate in asthma patients 2363Safety
In all the studies, the incidence and type of adverse events
reported were similar across treatment groups. A summary
of the most common drug-related adverse events recordedin each of the original trials is shown in Table 6. The
incidence of individual drug-related events was low and
similar in both treatment groups. There were no clinically
relevant differences between treatment groups in routine
laboratory parameters or clinically significant changes from
ARTICLE IN PRESS
Table 6 Most common drug-related adverse events during treatment.
Adverse event, n (%) Trial
12 13 14 15 (Stratum 1, GOAL
study)
SFC
(n ¼ 88)
FP
(n ¼ 89)
SFC
(n ¼ 95)
FP
(n ¼ 97)
SFC
(n ¼ 92)
FP
(n ¼ 89)
SFC
(n ¼ 198)
FP
(n ¼ 206)
Any drug-related AE 15 (17) 12 (13) 16 (17) 16 (16) 6 (7) 5 (6) 15 (8) 30 (15)
Candidiasis mouth/
throat
4 (5) 3 (3) 1 (1) 2 (2) 1 (1) 1 (1) 3 (2) 7 (3)
Throat irritation 1 (1) 4 (4) 4 (4) 6 (6) 2 (2) 1 (1) 0 0
Hoarseness/dysphonia 1 (1) 1 (1) 4 (4) 3 (3) 1(1) 1 (1) 7 (4) 8 (4)
Headaches 3 (3) 2 (2) 5 (5) 3 (3) 2 (2) 1 (1) 2 (1) 6 (3)
Cough 2 (2) 2 (2) 3 (3) 0 0 0 0 0
N.C. Barnes et al.2364baseline in 12-lead ECG recordings in the three 12 week IMT
studies were these endpoints were assessed.12–14 In addi-
tion, no clinically significant treatment differences in 24-h
urinary cortisols were observed.15Discussion
The main objective of this analysis was to identify the
patients, on short-acting b2-agonists alone, who would
benefit from IMT with SFC 50/100 g bd compared with FP
100 g bd alone. The initial analysis, based on treatment
response by baseline asthma characteristics (airflow limita-
tion/symptoms/rescue use), showed that patients with
either two or three baseline features of uncontrolled asthma
were significantly more likely to achieve guideline-defined
well controlled asthma on SFC therapy than on FP; patients
with three baseline features showing the greatest difference
between treatments. The subsequent integrated analyses
using data from patients with two or three baseline features
of uncontrolled asthma consistently showed that SFC was
significantly more effective than FP across a range of
endpoints.
These findings are pertinent in view of the most recent
treatment guidelines which do not recommend determining
treatment selection based on asthma severity but based on
asthma control. This paper aimed to address a dilemma
facing clinicians trying to implement these guidelines. All
patients were defined as having uncontrolled asthma and
this paper sought to divide them into easily recognisable
groups, on the basis of their baseline symptoms, to assist in
the decision of selecting the most effective ‘initial main-
tenance therapy’.
The results of the Asthma Insights and Reality Surveys
(AIR) showed across all regions that the understanding and
management of asthma control was poor when assessed
against the standards set in the GINA guidelines.5–8 In
Europe, the survey showed that 63% of adults and 46% of
children were deemed to have persistent asthma (based on
frequency and severity of symptoms), however, only 26%
were using anti-inflammatory medication and, specifically,only 23% of patients with that reported moderate persistent
asthma symptoms were taking inhaled corticosteroids.6
These data highlight that there are large numbers of
patients with uncontrolled asthma receiving no mainte-
nance therapy that could gain additional benefit from the
use of SFC as their IMT in place of ICS alone.
There are a number of clinical advantages to starting
patients on combination therapy. It has been suggested that
patients are more likely to comply with treatment if it is
effective and the more rapid improvement with combination
therapy and the greater likelihood of having asthma well
controlled may aid compliance.17,18 For healthcare provi-
ders there may be additional advantages. Poorly controlled
symptoms have been shown to be predictive of asthma
exacerbations,15 reinforcing the importance of achieving
and maintaining control of asthma early in the disease
course.4 The results of this integrated analysis therefore
support earlier intervention with SFC combination therapy
rather that ICS alone, in patients with two or three baseline
features of uncontrolled asthma, where the odds of patients
achieving guideline-defined well controlled status were 1.65
to over 2 times higher, respectively. Guideline-defined total
control of asthma was also achieved in some patients: the
results showing that these patients, despite a history of
substantial rescue use, symptoms and airflow limitation
were completely asthma-free for at least 7 out of their first
12 weeks of treatment. Further, the GOAL study showed that
an increasing proportion of patients could achieve either
guideline-defined well- or total control with step up
treatment beyond the first 12 weeks and that this control
could be maintained.15
The safety results of this integrated analysis are reassur-
ing highlighting no particular safety concerns with regard to
ECG measurements or adrenocortical suppression. However,
the studies are too short term and contain insufficient
numbers of subjects to address concerns over life threaten-
ing asthma or asthma deaths.
One of the limitations of these analyses is their post hoc
and exploratory nature and, as such, no multiplicity
adjustment was made for the large number of subgroup
analyses. It is reassuring, however, that the results are
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with current treatment guidelines, where ICS/LABA is
the preferred option if a patient’s asthma is severely
uncontrolled.4
In conclusion, patients on short-acting b2-agonists alone
with two or three features of uncontrolled asthma (moder-
ate to severe airflow limitation/daily symptoms/daily
rescue medication use) are most likely to achieve better
control, earlier, with SFC 50/100 g bd initial maintenance
treatment compared with FP 100 g bd alone.Acknowledgements
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